Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/13/2017 | 03:31pm CEST

TOKYO, Oct. 13 -- Eisai issued the following news release:

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), Toyama Chemical Co., Ltd. of the Fujifilm Group (Headquarters: Tokyo, President: Junji Okada, "Toyama Chemical") and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chief Executive Officer: Shigeru Uehara, "Taisho Pharmaceutical") announced today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET (R) Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Kenichi Fujita, "TaishoToyama").

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.

Iguratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying Anti- Rheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram (R) Tablets 25 mg and KOLBET (R) Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.

Targeted News Service, source News Service

Stocks mentioned in the article
ChangeLast1st jan.
EISAI CO., LTD -3.11% 10270 End-of-day quote.58.07%
FUJIFILM HOLDINGS CORP 0.44% 5056 End-of-day quote.7.44%
TAISHO PHARMACEUTICAL INDONESIA TBK PT --End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
09/17EISAI : LSTM led partnership receives funding to develop drug for treating two n..
AQ
09/07MERCK AND : Eisai and Merck Announce China National Medical Products Administrat..
AQ
09/07EISAI : and Merck Receive Chinese Agency Approval of Lenvima
AQ
09/06EISAI : Stephen Davies Appointed Vice President, Eisai Strategic Information Sys..
AQ
09/06EISAI : and Merck & Co., Inc., Kenilworth, Nj., USA. Announce China National Med..
AQ
09/05EISAI : And Merck & Co. Announce China NMPA Approval of First Approval for LENVI..
AQ
09/04EISAI : Notice regarding partial label change for vascular embolization device d..
AQ
09/04EISAI : Notice Regarding Partial Label Change for Vascular Embolization Device D..
AQ
09/03EISAI : Receives Approval for Partial Label Change for Vascular Embolization Dev..
AQ
08/31EISAI : Biogen and Eisai report new results from Phase lb trial of aducanumab
AQ
More news
News from SeekingAlpha
09/10PHARMACEUTICAL/BIOPHARMA SEPTEMBER M : Vanishing Uncertainty 
09/10WEEK IN REVIEW : Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO 
09/05Eisai's Lenvima OK'd in China for liver cancer 
09/02WEEK IN REVIEW : Nearly $1 Billion In Cross-Border China Biopharma Deals 
08/28Biogen's Alzheimer's candidate aducanumab maintains risk-benefit profile in l.. 
Financials (JPY)
Sales 2019 630 B
EBIT 2019 -
Net income 2019 56 247 M
Finance 2019 122 B
Yield 2019 1,46%
P/E ratio 2019 51,40
P/E ratio 2020 54,75
EV / Sales 2019 4,64x
EV / Sales 2020 4,71x
Capitalization 3 046 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 11 370  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD58.07%27 046
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092